Cargando…

Tooth Formation as Experimental Model to Study Chemotherapy on Tissue Development: Effect of a Specific Dose of Temozolomide/Veliparib

Background: Chemotherapy treatment of cancer in children can influence formation of normal tissues, leading to irreversible changes in their structure and function. Tooth formation is susceptible to several types of chemotherapy that induce irreversible changes in the structure of enamel, dentin and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Ansari, Sali, Jalali, Rozita, Bronckers, Antonius L. J. J., van Tellingen, Olaf, Raber-Durlacher, Judith, Nadjmi, Nasser, Brook, Alan Henry, de Lange, Jan, Rozema, Frederik R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322384/ https://www.ncbi.nlm.nih.gov/pubmed/35885982 http://dx.doi.org/10.3390/genes13071198

Ejemplares similares

The effect of a single injection of irinotecan on the development of enamel in the Wistar rats
por: Al‐Ansari, Sali, et al.
Publicado: (2017)

The Importance of Connexin 43 in Enamel Development and Mineralization
por: Al-Ansari, Sali, et al.
Publicado: (2018)

Oral Mucositis Induced By Anticancer Therapies
por: Al-Ansari, Sali, et al.
Publicado: (2015)

Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma
por: Gabrielson, Andrew, et al.
Publicado: (2015)

Taste and smell disturbances in patients with chronic oral graft vs. host disease: An observational study
por: Boor, Marlou, et al.
Publicado: (2022)

A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study
por: Sim, Hao-Wen, et al.
Publicado: (2021)

A Multi-Site Phase I Trial of Veliparib with Standard Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
por: Kleinberg, Lawrence, et al.
Publicado: (2023)

Exploring the role of oral microorganisms in the pathogenesis of mucositis by assessing their impact on metabolic activity and reproductive capacity of epithelial cells in vitro
por: Haverman, Thijs M., et al.
Publicado: (2020)

Pre-Chemotherapy Dental Screening: Is There Additional Diagnostic Value for a Panoramic Radiograph?
por: Zecha, Judith A. E. M., et al.
Publicado: (2023)

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
por: Pietanza, M. Catherine, et al.
Publicado: (2018)

Profile of veliparib and its potential in the treatment of solid tumors
por: Wagner, Lars M
Publicado: (2015)

Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma
por: Jue, Toni Rose, et al.
Publicado: (2017)

Efficacy and safety of veliparib plus chemotherapy for the treatment of lung cancer: A systematic review of clinical trials
por: Daei Sorkhabi, Amin, et al.
Publicado: (2023)

The Potential Contribution of Dental Foci and Oral Mucositis to Febrile Neutropenia in Patients Treated With Myelosuppressive Chemotherapy for Solid Tumors and Lymphoma
por: Zecha, Judith A. E. M., et al.
Publicado: (2022)

HGG-06. Phase 2 Study of Veliparib and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma without H3 K27M or BRAF Mutations: A Report from the Children's Oncology Group ACNS1721 Study
por: Karajannis, Matthias, et al.
Publicado: (2022)

The impact of the oral cavity in febrile neutropenia and infectious complications in patients treated with myelosuppressive chemotherapy
por: Zecha, Judith A. E. M., et al.
Publicado: (2019)

Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of Medulloblastoma
por: Buck, Jessica, et al.
Publicado: (2021)

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale
por: Isakoff, Steven J, et al.
Publicado: (2017)

Efficacy and safety of veliparib combined with traditional chemotherapy for treating patients with lung cancer: a comprehensive review and meta-analysis
por: Zhao, Guanhua, et al.
Publicado: (2023)

Effect of the PARP inhibitor veliparib on germ cell tumor cell lines
por: Schmidtova, Silvia, et al.
Publicado: (2022)

The Role of Na:K:2Cl Cotransporter 1 (NKCC1/SLC12A2) in Dental Epithelium during Enamel Formation in Mice
por: Jalali, Rozita, et al.
Publicado: (2017)

Local and Systemic Pathogenesis and Consequences of Regimen-Induced Inflammatory Responses in Patients with Head and Neck Cancer Receiving Chemoradiation
por: Russi, Elvio G., et al.
Publicado: (2014)

Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer
por: Owonikoko, Taofeek K, et al.
Publicado: (2014)

Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2()
por: de Gooijer, Mark C., et al.
Publicado: (2018)

Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors
por: Bartelink, Imke H., et al.
Publicado: (2017)

Blocking PARP activity with the inhibitor veliparib enhances radiotherapy sensitivity in endometrial carcinoma
por: Wang, Jing, et al.
Publicado: (2022)

Synthesis of Veliparib Prodrugs and Determination of Drug-Release-Dependent PARP-1 Inhibition
por: Borgini, Matteo, et al.
Publicado: (2023)

Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial
por: Mizuno, Mika, et al.
Publicado: (2022)

Oral Complications in Hematopoietic Stem Cell Recipients: The Role of Inflammation
por: Haverman, T. M., et al.
Publicado: (2014)

Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study
por: Ramalingam, Suresh S., et al.
Publicado: (2021)

Temozolomide Chemotherapy in Patients with Recurrent Malignant Gliomas
por: Yang, Seung-Ho, et al.
Publicado: (2006)

An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer
por: Stringer-Reasor, Erica M., et al.
Publicado: (2021)

Role of Photobiomodulation Therapy in Neurological Primary Burning Mouth Syndrome. A Systematic Review and Meta-Analysis of Human Randomised Controlled Clinical Trials
por: Hanna, Reem, et al.
Publicado: (2021)

Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study
por: Munasinghe, Wijith, et al.
Publicado: (2016)

Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer
por: Nishio, Shin, et al.
Publicado: (2017)

Sustained, Long-Term Maintenance of Remission with Single-Agent Veliparib in Recurrent Triple-Negative Breast Cancer
por: Kota, Karthik, et al.
Publicado: (2017)

Phase 1 dose‐escalation study of single‐agent veliparib in Japanese patients with advanced solid tumors
por: Nishikawa, Tadaaki, et al.
Publicado: (2017)

Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study
por: Werner, Theresa L., et al.
Publicado: (2018)

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours
por: Berlin, Jordan, et al.
Publicado: (2018)

In Vitro and In Vivo Efficacy of DNA Damage Repair Inhibitor Veliparib in Combination with Artesunate against Echinococcus granulosus
por: Li, Y. F., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_eis4obtjh72kmf56p6o5b92hrc